Scarica l'app Stockscreener
11.19
0.45%
0.05
Precedente Chiudi:
$11.14
Aprire:
$11.05
Volume 24 ore:
101.12K
Relative Volume:
0.49
Capitalizzazione di mercato:
$462.06M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.61%
1M Prestazione:
+12.01%
6M Prestazione:
-40.38%
1 anno Prestazione:
-51.45%
Intervallo 1D:
$10.76
$11.72
Intervallo di 1 settimana:
$10.76
$14.43
Portata 52W:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
1325 BOYLSTON STREET, BOSTON
Confronta RAPP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
11.19 | 462.06M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Rapport Therapeutics management to meet with Citizens JMP - TipRanks
Deutsche Bank AG Invests $41,000 in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Stifel reiterates buy rating for Rapport Therapeutics stock By Investing.com - Investing.com Nigeria
Citizens JMP maintains positive outlook on Rapport Therapeutics stock By Investing.com - Investing.com UK
Rapport Therapeutics Completes Enrollment for Phase 2a Trial - TipRanks
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - GlobeNewswire
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline - Nasdaq
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Monday - Defense World
Rapport Therapeutics to Host 2025 Investor and Analyst Day - GlobeNewswire
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - Yahoo Finance
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Grows Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Buys 5,634 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics, Inc. SEC 10-Q Report - TradingView
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - The Manila Times
(RAPP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co. - Defense World
Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by Geode Capital Management LLC - Defense World
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Validea Kenneth Fisher Strategy Daily Upgrade Report3/25/2025 - Nasdaq
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Non sono disponibili dati finanziari per Rapport Therapeutics Inc (RAPP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Rapport Therapeutics Inc Azioni (RAPP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Apr 15 '25 |
Sale |
9.57 |
8,500 |
81,310 |
460,642 |
| Bredt David | Chief Scientific Officer |
Mar 14 '25 |
Sale |
10.85 |
8,500 |
92,205 |
469,142 |
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):